Le Lézard
Classified in: Health, Business
Subjects: LIC, BFA

Curiox Biosystems to Advance Next-Generation Cancer Cell Therapies Through Collaboration with Leading Cancer Researcher


BOSTON, Sept. 13, 2023 /PRNewswire/ -- Curiox Biosystems, a global leader in providing innovative and automated sample preparation solutions for accurate and reproducible cell analysis, is pleased to announce its collaboration with Dr. Marco Ruella, an Assistant Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania (Penn), to support efforts in the development of next-generation cancer cell therapies.

We are collaborating to advance therapeutic development through accurate and reproducible cell analytics.

The collaboration will focus on leveraging Curiox Biosystems' next-generation sample preparation platform alongside Dr. Ruella's pioneering expertise in cell and gene therapies to establish improved metrics of cellular analysis.

"We are excited to embark on this collaboration with Dr. Ruella and Penn," stated the Leadership Team of Curiox Biosystems. "We are collaborating to advance therapeutic development in the field of cell therapy through automation that provides accurate and reproducible cell analytics."

Dr. Marco Ruella, an internationally recognized expert in cellular immunotherapies, brings his extensive experience in the development of innovative treatments, such as chimeric antigen receptor T-cell (CART) to this collaboration. His deep experience, including with industry collaborations, will be instrumental in this partnership to advance automated cell sample preparation in cell and gene therapy workflows.

"We are thrilled to partner with Dr. Marco Ruella and Penn to establish a collaboration around Curiox's automated cell sample preparation platform," said Dr. Namyong Kim, CEO of Curiox Biosystems. "With this partnership we aspire to improve cell therapies by automating critical steps in the workflow which we hope will ultimately benefit patients worldwide."

About Curiox Biosystems, Inc.

Next-generation therapies deserve next-generation sample prep solutions. Curiox has brought together surface chemistry and instrumentation expertise to overcome critical challenges slowing the pace of life-science research. By focusing on common assay steps and workflows where miniaturization and automation are currently underutilized, the company has developed innovative technologies that simultaneously improve both productivity and data quality, accelerating the pace of therapeutic development.

Contact:
Mahi M. Banday
DVM, PhD
Executive Vice President/GM of Product
Marketing and Operations
781-491-5289
mahib@curiox.com

SOURCE Curiox Biosystems


These press releases may also interest you

at 15:30
Healthcare Marketing Experts Team Up To Share Best Practices For Reaching Doctors
The professional membership group of the American Hospital Association focused on healthcare marketing has enlisted experts from the advertising agency universe and the provider data sector to share insights about the best methods for reaching and...

at 15:20
Chronic virus found in long COVID gut up to 2 years post-infection
Team famous for HIV breakthroughs demonstrates both persistent COVID virus and widespread immune activation in long COVID; provides clear targets for treatment Key points: SARS-CoV-2 double-stranded RNA indicative of viral replication was found in...

at 15:05
CloudMD Receives Court Approval of Proposed Transaction with CPS Capital
CloudMD Software & Services Inc. (the "Company" or "CloudMD"), an innovative health services company transforming the delivery of care, is pleased to announce that it has received a final order from the Supreme Court of British Columbia approving...

at 14:57
TEAMSTERS AT WATSONVILLE COMMUNITY HOSPITAL UNANIMOUSLY RATIFY CONTRACT
Workers at Watsonville Community Hospital represented by Teamsters Local 853 have voted unanimously to ratify a collective bargaining agreement. The new three-year contract includes significant wage increases, a strong benefits package with Teamsters...

at 14:55
Anti-Inflammatory Therapeutics Market size is set to grow by USD 38.7 billion from 2024-2028, Increase in off-label use to boost the market growth, Technavio
The global anti-inflammatory therapeutics market size is estimated to grow by USD 38.7 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 6.3% during the forecast period. Increase in off-label use is...

at 14:45
Pulse Biosciences, Inc. Announces the Closing of its Rights Offering
Pulse Biosciences, Inc. (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, announced today the closing of its rights offering and the final results...

More news about Health...


News published on and distributed by: